ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
0.3605
-0.0264 (-6.82%)
At close: Mar 31, 2025, 4:00 PM
0.3758
+0.0153 (4.24%)
After-hours: Mar 31, 2025, 5:45 PM EDT
ReShape Lifesciences Employees
ReShape Lifesciences had 29 employees as of December 31, 2023. The number of employees decreased by 11 or -27.50% compared to the previous year.
Employees
29
Change (1Y)
-11
Growth (1Y)
-27.50%
Revenue / Employee
$282,172
Profits / Employee
-$243,690
Market Cap
1.19M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RSLS News
- 10 days ago - RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS - Business Wire
- 21 days ago - ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - GlobeNewsWire
- 4 weeks ago - ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX - GlobeNewsWire
- 6 weeks ago - ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering - GlobeNewsWire
- 2 months ago - ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology - GlobeNewsWire
- 2 months ago - ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys - GlobeNewsWire
- 4 months ago - ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - GlobeNewsWire